QNRX

Quoin Pharmaceuticals, Ltd.

NasdaqHealthcarePharmaceutical Preparations

Insider activity for last month from 08/03 to 09/03. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Latest filingSep 02, 2026Most recent Form 4
Total buying8 buys
Total selling$00 sells
Net open-market5 insiders
Open-market mix
Buy vs sell distribution by transaction count
8 transactions
8 buys100%·0%0 sells

Insider activity report

Monthly open-market purchase and sale counts
Buys Sells
1050-5-10transactionsAug 2026 buys: 8 transactions · unknown value8AugSep

Transaction codes

By Form 4 transaction code in selected period
10transactions
  • P · Open-market buys · dominant8 · 80%
  • A · Grants / awards2 · 20%

Activity by reported role

A joint filing can contribute to multiple roles
10transactions
  • Director · dominant4 · 40%
  • Chief executive officer2 · 20%
  • Chief financial officer2 · 20%
  • COO2 · 20%

Distinct insiders active

Reporting-owner CIKs by month · peak Aug 2026 (5)
Aug 2026Sep 2026
5distinct insiders in 2 months

Reported Holdings After

Separated by insider, security, and ownership type
40.4k34.2kAug 27, 2026 · 34,218 shares owned afterAug 31, 2026 · 40,364 shares owned afterAug 27, 2026Aug 31, 2026
40,364Aug 31, 2026
Langer DennisADSs · Direct
56.2k56.2kAug 27, 2026 · 56,243 shares owned afterAug 27, 2026Aug 27, 2026
56,243Aug 27, 2026
Culverwell Anthony JamesOrdinary Warrants (Right to Buy) · Direct
3.1k3.1kAug 31, 2026 · 3,073 shares owned afterAug 31, 2026Aug 31, 2026
3,073Aug 31, 2026
Lawlor Sally BridgetOrdinary Warrants (Right to Buy) · Direct
5.1k5.1kAug 31, 2026 · 5,122 shares owned afterAug 31, 2026Aug 31, 2026
5,122Aug 31, 2026
Lawlor Sally BridgetADSs · Direct
10.7k10.7kAug 31, 2026 · 10,684 shares owned afterAug 31, 2026Aug 31, 2026
10,684Aug 31, 2026
Myers MichaelADSs · Direct
37.7k37.7kAug 31, 2026 · 37,713 shares owned afterAug 31, 2026Aug 31, 2026
37,713Aug 31, 2026
Myers MichaelOrdinary Warrants (Right to Buy) · Direct
10.2k10.2kAug 31, 2026 · 10,245 shares owned afterAug 31, 2026Aug 31, 2026
10,245Aug 31, 2026
Carter Denise P.ADSs · Direct
37.7k37.7kAug 31, 2026 · 37,709 shares owned afterAug 31, 2026Aug 31, 2026
37,709Aug 31, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells red
0 active days
Aug 03Sep 03
LessMore

Filing detail checks

Secondary metrics for the selected period
Largest buy-
Largest sale-
10b5-1 detected0
Amended rows0

QNRX transaction history

Filters apply within this company and selected period by default
Reset
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date

No transactions match your filters

Once the backend ingests and parses SEC filings, they will appear here. Try removing a filter or picking a wider date range.

Quoin Pharmaceuticals, Ltd. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at Quoin Pharmaceuticals, Ltd.?

Carter Denise P., Myers Michael, Lawlor Sally Bridget, Culverwell Anthony James, LANGER DENNIS.

When was the latest reported open-market purchase?

Carter Denise P. reported a buy on Aug 31, 2026 valued at an unknown value. Read the SEC filing.

When was the latest reported open-market sale?

No code-S sale is available for this period.

What is the recent purchase and sale balance?

The net open-market value is unknown because at least one matching code-P or code-S row lacks a value.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.